CounterPunch WEEKEND EDITION AUGUST 29-31, 2014
After working for a series of unsavory financial institutions for 15 years, I accepted a position as a database administrator at Memorial Sloan-Kettering Cancer Center (MSKCC) in 1983 with an eager sense of anticipation. Finally I would be doing something professionally that was more in sync with my political values. Instead of using my skills to keep track of pension trust portfolios, I would be creating a data infrastructure for patient care.
For more than a year I worked on developing a data model based on “normalized” relationships that sought to eliminate redundancies and provide a reliable foundation for applications development. A few months after I presented the model to management, I learned that all my work was in vain. The hospital had decided to buy a package from SMS, inc. that was considered nonpareil when it came to debt collection. As happened too often, a loved one would check into the hospital for a couple of months of very expensive and painful treatments that came to an end with the patient’s death. Since the survivors often had a tendency to ignore the astronomical bills that went along with such an exercise in futility, the hospital decided to purchase a system that was very good at dunning if nothing else. That decision left me feeling deflated. Once again money ruled.
When I received an invitation to review “Second Opinion: Laetrile at Sloan-Kettering”, a documentary described as “the remarkable true story of a young science-writer at Memorial Sloan-Kettering Cancer Center, who risked everything by blowing the whistle on a massive cover-up involving a promising cancer therapy”, I knew that this was one I could not miss. (The film opens at Cinema Village in NYC on August 29, and at Laemmle Music Hall in LA on September 5. A national release will follow.)